Tislelizumab Clinical Trials (97 Recruiting)

Showing 1–20 of 112 trials

A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States

Esophageal Squamous Cell CarcinomaAdvanced Unresectable Gastric AdenocarcinomaAdvanced Gastroesophageal Adenocarcinoma

BeOne Medicines30 enrolled6 locationsNCT07554521

Recruiting

Phase 2

Tislelizumab in People With Colorectal Cancer

Colorectal, Cancer

Memorial Sloan Kettering Cancer Center40 enrolled3 locationsNCT06529523

Recruiting

Phase 2Phase 3

A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)

Esophageal Squamous Cell Carcinoma

Sichuan Baili Pharmaceutical Co., Ltd.90 enrolled1 locationNCT07554456

Recruiting

Phase 2

Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma (HNSCC)Neoadjuvant TherapyHead and Neck Squamous Cell Carcinoma+1 more

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine182 enrolled1 locationNCT07601737

Recruiting

Phase 1

A Study of BG-C477 in Participants With Advanced Solid Tumors

Advanced Solid Tumors

BeOne Medicines310 enrolled54 locationsNCT06596473

Recruiting

Phase 1

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

Advanced Solid Tumor

BeOne Medicines308 enrolled37 locationsNCT06233942

Recruiting

Phase 1

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

Metastatic Hepatocellular CarcinomaLocal Advanced Hepatocellular CarcinomaAlpha-fetoprotein (AFP)-Producing Gastric Cancer+2 more

BeOne Medicines392 enrolled47 locationsNCT06427941

Recruiting

Phase 2

Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC

NSCLC (Non-small Cell Lung Cancer)

Sun Yat-sen University160 enrolled1 locationNCT07609121

Recruiting

Phase 3

Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.

Adenocarcinoma

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.752 enrolled106 locationsNCT07385703

Recruiting

Phase 2Phase 3

SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer

Double-blind

Sinocelltech Ltd.410 enrolled1 locationNCT07662395

Recruiting

Phase 1

A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer

Pancreatic Cancer

Memorial Sloan Kettering Cancer Center20 enrolled7 locationsNCT07671339

Recruiting

A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)

Extensive-stage Small-cell Lung CancerAdvanced Non-Small Cell Lung Cancer

BeOne Medicines440 enrolled1 locationNCT07652736

Recruiting

Phase 1

EVM16 Injection as a Single and Combination With Tislelizumab in Solid Tumors

Advanced or Recurrent Solid Tumors

Peking University78 enrolled2 locationsNCT06541639

Recruiting

Phase 1Phase 2

Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma

Extranodal NK T Cell LymphomaNK/T-cell LymphomaRelapsed or Refractory NK/T-Cell Lymphoma

Rong Tao107 enrolled1 locationNCT07502768

Recruiting

Phase 1

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

Gastric CancerAdvanced Solid TumorTNBC - Triple-Negative Breast Cancer+1 more

SillaJen, Inc.260 enrolled17 locationsNCT05768932

Recruiting

Phase 2

A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T

Large B-cell Lymphoma

University Health Network, Toronto76 enrolled1 locationNCT06167785

Recruiting

Phase 1

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Advanced Solid TumorSolid Tumor

BeOne Medicines217 enrolled28 locationsNCT05981703

Recruiting

Phase 2

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Colorectal, CancerMinimal Residual DiseasectDNA+3 more

M.D. Anderson Cancer Center20 enrolled1 locationNCT07136077

Recruiting

Phase 1Phase 2

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Non-small Cell Lung CancerPancreatic Ductal Adenocarcinoma

Phanes Therapeutics40 enrolled6 locationsNCT05431270

Tislelizumab Clinical Trials

A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors

A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States

Tislelizumab in People With Colorectal Cancer

A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)

Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

A Study of BG-C477 in Participants With Advanced Solid Tumors

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC

Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.

SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer

A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer

A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)

EVM16 Injection as a Single and Combination With Tislelizumab in Solid Tumors

Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)